LINK: https://bswhealth.webex.com/bswhealth/j.php?MTID=m0a4e9a203b01e737e50d8b92eeedcce9

OBJECTIVES: Upon completion of this activity, the participant should be able to:  (1) Discuss the patient's case and treatment in view of the NCCN Guidelines and the molecular findings, (2) Enumerate how the molecular findings and the literature around these findings may affect the treatment of the patient, (3) Generate an appropriate treatment plan based on the science and literature discussed in the tumor board, (4). Communicate the discussion and its results to the treating team for each patient.

PLANNER/MODERATOR DISCLOSURE: Robert Mennel, MD, hase no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  Michelle Shiller, MD is/was a speaker/advise board for Astra Zeneca, Merck, Genertech, Mirati, Amgen, Takeda, and BMS Companies.

All relevant financial relationships have been mitigated.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information, please contact Rachel Waller at [email protected]